Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company founded in November 2017 with operations in Rehovot, Israel and Wilmington, Delaware. The company is developing AL101 and AL102, best-in-class gamma secretase (pan‑Notch) inhibitors, with clinical and preclinical studies underway. AL101 is in Phase 2 for adenoid cystic carcinoma (ACC) and Ayala intends to initiate a Phase 2 trial in triple negative breast cancer (TNBC) bearing Notch activating mutations/fusions. AL102 is being investigated in hematologic malignancies, and Ayala is collaborating with Novartis in multiple myeloma. The FDA’s Office of Orphan Products Development has granted Orphan Drug Designation to AL101 for potential treatment of ACC. The company is focused on advancing its lead candidates through clinical development.

Total raised

$30M

Funding rounds

1

Latest round

Series B

Latest activity

May 2019